• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Evolent Health Appoints Seth R. Frank as Vice President, Investor Relations

    12/1/21 8:00:00 AM ET
    $EVH
    $HNGR
    $MDRX
    Other Consumer Services
    Consumer Discretionary
    Medical Specialities
    Health Care
    Get the next $EVH alert in real time by email

    WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community.

    "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-term relationships with institutional investors, analysts and other stakeholders across the health care services sector, as well as health care information technology specifically. With his expertise in originating strategic IR programs, we anticipate Seth will accelerate the investment community's knowledge of Evolent's business as we continue to deliver on our strategy to create long-term value for shareholders." 

    Seth joins Evolent from Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic services, where he served as Vice President of Treasury and Investor Relations for nearly four years. Previously, Seth was Vice President of Investor Relations at Allscripts (NASDAQ:MDRX), a health care information technology company, for nearly eight years; prior to that, Seth worked in several other investor relations and financial communications roles. Prior to beginning his corporate career in 2006, Seth was an equity analyst and capital markets professional at several firms including Morgan Stanley, SunTrust and A.G. Edwards where he covered the health care information technology, distribution and medical technology industries. Seth received his undergraduate degree from Emory University, an M.S. as a Physician Assistant from the University of Colorado School of Medicine, and also attended the Master of Public Health program at Yale University. He holds the Investor Relations Charter (IRC®) from the National Investor Relations Institute. 

    Evolent Health Logo (PRNewsfoto/Evolent Health)

    About Evolent Health

    Evolent Health (NYSE:EVH) delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management, and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation, and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.

    CONTACTS:

    Investors:

    Seth R. Frank

    Vice President, Investor Relations

    Evolent Health, Inc.

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-health-appoints-seth-r-frank-as-vice-president-investor-relations-301434968.html

    SOURCE Evolent Health

    Get the next $EVH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVH
    $HNGR
    $MDRX

    CompanyDatePrice TargetRatingAnalyst
    Evolent Health Inc
    $EVH
    1/10/2025$15.00Buy
    Needham
    Evolent Health Inc
    $EVH
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    Evolent Health Inc
    $EVH
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    Evolent Health Inc
    $EVH
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    Evolent Health Inc
    $EVH
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    Evolent Health Inc
    $EVH
    4/22/2024$40.00Buy
    Citigroup
    Veradigm Inc.
    $MDRX
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    Evolent Health Inc
    $EVH
    3/1/2024$45.00Outperform
    Oppenheimer
    More analyst ratings

    $EVH
    $HNGR
    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:20:54 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:18:12 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Jelinek Richard M bought $273,750 worth of shares (30,000 units at $9.12) (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:16:20 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/14/25 3:07:26 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    SEC Form 10-Q filed by Evolent Health Inc

    10-Q - Evolent Health, Inc. (0001628908) (Filer)

    8/11/25 6:27:45 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Health Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Evolent Health, Inc. (0001628908) (Filer)

    8/7/25 4:15:43 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Shams Aammaad covered exercise/tax liability with 2,567 shares, decreasing direct ownership by 3% to 72,899 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    8/5/25 4:11:35 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Chief Executive Officer Blackley Seth was granted 67,150 shares, increasing direct ownership by 9% to 829,367 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    7/3/25 7:12:25 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    General Counsel Weinberg Jonathan was granted 23,394 shares, increasing direct ownership by 10% to 254,179 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    7/3/25 7:10:27 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Evolent Health with a new price target

    Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00

    1/10/25 7:49:47 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    BTIG Research reiterated coverage on Evolent Health with a new price target

    BTIG Research reiterated coverage of Evolent Health with a rating of Buy and set a new price target of $29.00 from $36.00 previously

    12/3/24 7:52:53 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Health downgraded by Stephens with a new price target

    Stephens downgraded Evolent Health from Overweight to Equal-Weight and set a new price target of $16.00 from $38.00 previously

    11/8/24 7:50:07 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veradigm Inc.

    SC 13G - Veradigm Inc. (0001124804) (Subject)

    11/14/24 4:05:58 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/14/24 1:11:13 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Other Consumer Services

    Define Ventures Appoints Carolyn Magill as Venture Partner

    The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

    3/11/25 5:30:00 AM ET
    $EVH
    $HIMS
    $LVGO
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    Veradigm Announces Board Expansion and Changes

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

    2/20/25 4:02:00 PM ET
    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $EVH
    $HNGR
    $MDRX
    Financials

    Live finance-specific insights

    View All

    Evolent Announces Second Quarter 2025 Results

    WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

    8/7/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    7/14/25 8:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent reiterates Q2 and full year guidance for Adjusted EBITDA

    Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M. John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thi

    6/20/25 6:30:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolent Announces Second Quarter 2025 Results

    WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

    8/7/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    NYSE Content Advisory: Pre-market update + Wall Street anticipates Fed's next move

    NEW YORK, July 29, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on July 29th Stocks are fractionally higher Tuesday morning following another record close on Monday for the S&P 500, though the large-cap index only saw a slight gain during yesterday's session.More than 150 companies will report earnings this week. The week will be headlined by Microsoft, Meta, Amazon, and Apple, which will release quarterly figures and guidance in the coming days.The

    7/29/25 8:55:00 AM ET
    $EVH
    $ICE
    Other Consumer Services
    Consumer Discretionary
    Investment Bankers/Brokers/Service
    Finance

    Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    7/14/25 8:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary